Alnylam Pharmaceuticals logo

ALNY Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Healthcare Biotechnology SIC: Unknown CIK: 1178670

Transaction DateRecipientSharesTypePriceValue